within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AX03_Temozolomide;
model Temozolomide 
   extends Pharmacolibrary.Drugs.ATC.L.L01AX03;

  annotation(Documentation(
    info ="<html><body><p>Temozolomide is an oral alkylating agent, primarily used in the treatment of certain brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. It is approved for use in many countries and is considered a standard of care for high-grade gliomas.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (glioblastoma), mixed sexes, typical age range 18-70 years, normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Büsker, S, et al., &amp; Peyrl, A (2022). Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. <i>Cancer chemotherapy and pharmacology</i> 89(5) 617–627. DOI:<a href=&quot;https://doi.org/10.1007/s00280-022-04424-4&quot;>10.1007/s00280-022-04424-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35355137/&quot;>https://pubmed.ncbi.nlm.nih.gov/35355137</a></p></li><li><p>Beale, P, et al., &amp; Brada, M (1999). Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. <i>Cancer chemotherapy and pharmacology</i> 44(5) 389–394. DOI:<a href=&quot;https://doi.org/10.1007/s002800050994&quot;>10.1007/s002800050994</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10501912/&quot;>https://pubmed.ncbi.nlm.nih.gov/10501912</a></p></li><li><p>Reyderman, L, et al., &amp; Wirth, M (2004). Disposition and pharmacokinetics of temozolomide in rat. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 34(5) 487–500. DOI:<a href=&quot;https://doi.org/10.1080/00498250410001685737&quot;>10.1080/00498250410001685737</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15370964/&quot;>https://pubmed.ncbi.nlm.nih.gov/15370964</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Temozolomide;
